Navigation Links
Cardinal Health Reports Third Quarter Results
Date:5/1/2008

the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at http://www.cardinalhealth.com .

(1) Non-GAAP diluted EPS from continuing operations: Non-GAAP earnings

from continuing operations divided by diluted weighted average shares

outstanding.

(2) Non-GAAP operating earnings: Operating earnings/(loss) excluding

special items and impairment charges and other.

(3) Non-GAAP earnings from continuing operations: Earnings/(loss) from

continuing operations excluding special items and impairment charges

and other, both net of tax.

A reconciliation of the differences between these non-GAAP financial measures and their most directly comparable GAAP financial measures is provided in the attached tables and at http://www.cardinalhealth.com .

This news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. The most significant of these uncertainties are described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports (including all amendments to those reports) and exhibits to those reports, and include (but are not limited to) the following: competitive pressures in Cardinal Health's various lines of business; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships; uncertainties relating to timing of generic and branded pharmaceutical introductions and the frequency or rate of branded pharmaceutical price appreciation or generic pharmaceutical price deflation; changes in the dist
'/>"/>

SOURCE Cardinal Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related medicine news :

1. Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
2. Cardinal Health Names CEO R. Kerry Clark as Chairman; Company Founder Robert D. Walter to Retire After 36 Years
3. Cardinal Health To Announce First-Quarter Results on November 5
4. Cardinal Health Announces Sector Management Change
5. Cardinal Health Reports First Quarter Results
6. Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved
7. Cardinal Health Receives DEA Order to Temporarily Cease Distribution of Controlled Substances from Auburn, Wash. Facility
8. Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHIS 5 Million Lives Campaign
9. Cardinal Health to Cease Distribution of Controlled Substances from Florida Facility
10. Cardinal Health to Announce Second-Quarter Results on January 29
11. Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sheridan Healthcare, Inc. , ... today announced that Adam Blomberg, MD, the national ... present at the Society for Healthcare Strategy & ... . The conference will be held October 12-15 ... a four-day conference that draws in more than ...
(Date:9/30/2014)... TN (PRWEB) September 30, 2014 ... of people throughout the United States and worldwide. ... Parkinson’s Disease are diagnosed each year, adding to ... with the disease. Approximately 400,000 people in the ... million worldwide. Add to these statistics the 2.4 ...
(Date:9/30/2014)... 2014 (HealthDay News) -- In books and movies, plots involving ... Now, new research suggests that the stereotype may be ... at data on more than 12,000 people from Finland. ... Turku, Finland, found that women typically preferred men who were ... throughout their lives. On the other hand, men tended ...
(Date:9/30/2014)... Bank, New Jersey (PRWEB) September 30, 2014 ... largest not-for-profit visiting nurse association—is pleased to announce that ... was honored with a NJBIZ “40 Under 40” ... of New Jersey’s most accomplished young businessmen and women ... who share a commitment to business growth, professional excellence ...
(Date:9/30/2014)... FL (PRWEB) September 30, 2014 ... company focused on the peripheral nerve repair market, announced ... during the American Society for Surgery of the ... week in Boston. , The ASSH ... the Utilization of Processed Nerve Allografts for Large Gap ...
Breaking Medicine News(10 mins):Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 2Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5
... estimated 2 million women in the United States are ... the chronic and abnormal swelling of the arm, chest, ... treatment. While physicians will recommend proven techniques to manage ... that patients often won,t follow the recommendations, or they ...
... times more apt to develop the lung artery disorder, study ... four times more likely to develop a debilitating and potentially ... shows. , Pulmonary hypertension is caused by high blood pressure ... who suffer from the condition can become tired, dizzy and ...
... the question, do barriers to health care for ... tuberculosis? The study, published in the November 15, ... and now available online, suggests that undocumented immigrants ... than documented immigrants or U.S.-born patients, resulting in ...
... CEO John G. Schulte with Chairman ... Emile J. Geisenheimer., ... lawsuit on behalf of those who purchased Spectranetics Company,stock (Nasdaq: ... officer violated U.S. securities laws through illegal,marketing practices and false statements ...
... of their Regional PPO Network Area Pay ... ... Life Insurance Company,of America (Guardian), a leading provider of employee and ... Extended Access "travel network" for its health plan members.,Members utilizing health ...
... Pittsburgh-based Foundation,Radiology Group (FRG) signed a multi-year ... exclusive provider of diagnostic,imaging services effective December 31, ... in Coudersport Pennsylvania,and services multiple counties in north ... provides a wide range of primary and,secondary health ...
Cached Medicine News:Health News:MU study identifies patient strategies for managing symptoms of lymphedema 2Health News:MU study identifies patient strategies for managing symptoms of lymphedema 3Health News:Women at Higher Risk for Pulmonary Hypertension 2Health News:Health-care barriers for undocumented immigrants: Raising tuberculosis risk? 2Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 2Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 3Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 4Health News:Guardian Provides National Access to In-Network Medical Benefits 2Health News:Foundation Radiology Group Announces Multi-Year Deal with Charles Cole Memorial Hospital 2
(Date:9/30/2014)... 2014 Investor-Edge has initiated coverage ... IMMU ), Aeterna Zentaris Inc. (NASDAQ: AEZS ... Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences ... can be accessed at: http://investor-edge.com/register . ... at 4,505.85, down 0.14%, the Dow Jones Industrial Average ...
(Date:9/30/2014)... , Sept. 30, 2014 It is evident from ... market is not performing upto expectations due to the lack ... asscoaited with the intake of omega-3 fatty acids. Among omega-3 ... the fish oil, attributed to the large vegetarian population in ... omega-3 polyunsaturated fatty acid (PUFAs) ingredients is in growth stage ...
(Date:9/30/2014)... , Sept. 30, 2014 CytRx Corporation ... and development company specializing in oncology, today announced ... trial evaluating aldoxorubicin compared to topotecan in subjects ... have relapsed or were refractory to prior chemotherapy. ... chemotherapeutic agent, doxorubicin. CytRx has received Orphan Drug ...
Breaking Medicine Technology:Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 2Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 4Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 5Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5
... 2007 - Corgenix Medical,Corporation (OTC BB: CONX) ... data demonstrating a significant correlation,between serum levels ... disease. The data was presented at,the XXIst ... and,Hemostasis (ISTH) in Geneva, Switzerland., Data released ...
... of rHuPH20 with Humira Estimated to ... from 64% to 100%,-, SAN DIEGO, ... Inc. , a biopharmaceutical company developing ... that,final results of the Enhanze(TM) Technology ...
Cached Medicine Technology:Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 2Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5
... The AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is ... performance. Powerful saline jets create a low ... a vacuum effect. Thrombus is drawn into ... the jets, and removed from the body.,AngioJet ...
... combined with a stimulation lead ... Temporary Pacemaker can be used ... pacing is indicated. The device ... as well as diagnostic purposes ...
... a unique left ventricular assist device that helps ... being used in a small group of patients ... of an FDA-approved Feasibility Study. The patient can ... power source for minutes or hours. The Kantrowitz ...
... new Bicycle Ergometer ... braking system which ... reliable service while ... The hyperbolic workload ...
Medicine Products: